Fiocruz deal with WuXi Biologics will strengthen Brazil's health industrial base

30 March 2026

Fiocruz and the Chinese company WuXi Biologics (HKEX: 2269) have signed a memorandum of understanding (MoU) focused on creating technological capabilities and strengthening Brazil's health industrial base. The agreement was formalized during an official mission to China led by the Minister of Health, Alexandre Padilha.

The initiative lays the groundwork for structured international cooperation in the areas of research, technological development, training, and large-scale production of immunobiologicals. The Minister of Health emphasized that the partnership strengthens Fiocruz’s international role in the field of biological products for the Sistema Único de Saúde (SUS) and in addressing global health challenges.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK